Author's response to reviews

Title: Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report

Authors:

Javier A Neyra (javo_ny@hotmail.com)
Natalia A Rocha (NATALIA.DEALBUQUERQUEROCHA@phhs.org)
Rhea Bhargava (bhargavar@umkc.edu)
Omkar U Vaidya (ovaidya@yahoo.com)
Allen R Hendricks (Allen.Hendricks@UTSouthwestern.edu)
Aylin R Rodan (Aylin.Rodan@UTSouthwestern.edu)

Version: 3
Date: 20 April 2015

Author's response to reviews: see over
April 12, 2015

Re: Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone

Dear Editor:

On behalf of the authors, I am pleased to submit our manuscript “Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone” to your prestigious journal to be taken into consideration for publication.

We report a case of biopsy-proven rhabdomyolysis-induced acute kidney injury in a cancer patient acutely exposed to denosumab and abiraterone. To our knowledge, this is the first case report of rhabdomyolysis in this setting. Denosumab and abiraterone were approved by the United States Food and Drug Administration in 2011 for the treatment of metastatic castration-resistant prostate cancer and are not uncommonly used in this setting. Our case exposes the need for nephrologists to be aware of this potential complication and to further investigate the effect of these drugs on muscle cells and determine novel risk factors for rhabdomyolysis.

There is bona fide agreement among all the authors and there are no conflicts of interest for any of the authors.

With kind regards,

Javier Neyra
Javier A. Neyra, M.D.